Induction of CYP3A4 or MDR1 by vitamin E could potentially lower the efficacy of any drug metabolized by CYP3A4 or MDR1.
What does MEF1 stand for?
MEF1 stands for MDR1 (Multi-Drug Resistance 1) Promoter-Enhancing Factor 1
This definition appears somewhat frequently and is found in the following Acronym Finder categories:
- Science, medicine, engineering, etc.
See other definitions of MEF1
- Abbreviation Database Surfer
- « Previous
- Next »
- Mobility Enhancement Fund
- Modernized E-File (IRS)
- Modified Energy Factor
- Montville Education Foundation
- Mother Earth Foundation (Philippines)
- Mouse Embryo Feeder (cells)
- Mouse Embryonic Fibroblast
- Movies Explained For (YouTube)
- Museo Paleontológico Egidio Feruglio (Patagonia, Argentina)
- Marine Expeditionary Force (Forward)
- Motor-Evoked Field 1
- Mitochondrial Elongation Factor-G (genetics)
- Myocyte Enhancer Factor 2
- Maximal Expiratory Flow at 25% of Forced Vital Capacity
- Maximum Expiratory Flow at 25 Percent
- Mocyte Enhancer Binding Factor-2A
- Maximal Expiratory Flow at 40 Percent
- Maximal Expiratory Flow at 50% (respiratory function)
- Maximal Expiratory Flow at 50% of Vital Flow Capacity
- Massachusetts Educational Financing Authority
Samples in periodicals archive:
All of the current PIs are substrates for the P-glycoprotein efflux pump in the small intestine, and polymorphisms in the multidrug transporter MDR1 gene encoding P-glycoprotein may have significant implications for protease inhibitor exposure, efficacy and toxicity Polymorphisms in drug transporters with potential relevance to antiretroviral therapy include P-glycoprotein (PIs, zidovudine, nevirapine) and organic anion transporters (OATs) (tenofovir) Pharmacogenomics Defined It is widely recognized that all classes of antiretroviral agents have multiple effects other than suppression of HIV replication and are associated with many adverse effects, some of which can be life threatening].
As shown in Figure 6, BPA significantly induced the expression of mRNA encoding the PXR target genes CYP3A4, UGT1A1, and MDR1 in a dose-dependent manner compared with solvent controls.
More importantly, the direct evidence indicating that P-gp is responsible, in part, for acquisition of ATRA resistance in APL cells came from the experiment using ribozymes, which are able to target MDR1 RNA by a catalytic activity.
MDR1 encodes P-glycoprotein, a key protein involved in drug transport that is known to modulate drug disposition.
However, cells that had the atypical codon in combination with two other mutations in MDR1 pumped out some drugs with above-average effectiveness and others with below-average success.
P-glycoprotein, which is a membrane protein that functions as an exporter of xenobiotics from cells, is a product of the MDR1 gene.